Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor

PURPOSE: To report the results of switching treatment to vascular endothelial growth factor (VEGF) Trap-Eye (aflibercept) in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) refractory to anti-VEGF (ranibizumab and bevacizumab). METHODS: This is a retros...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Korean J Ophthalmol
Hlavní autoři: Moon, Da Ru Chi, Lee, Dong Kyu, Kim, Soon Hyun, You, Yong Sung, Kwon, Oh Woong
Médium: Artigo
Jazyk:Inglês
Vydáno: The Korean Ophthalmological Society 2015
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4520865/
https://ncbi.nlm.nih.gov/pubmed/26240506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3341/kjo.2015.29.4.226
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky